Lambrinakos-Raymond Kristen, Dubrovsky Alexander Sasha, Gagnon Isabelle, Zemek Roger, Burstein Brett
Division of Pediatric Emergency Medicine, Department of Pediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada.
UP Centre for Pediatric Emergencies, Brossard, Quebec, Canada.
J Neurotrauma. 2022 Jan;39(1-2):144-150. doi: 10.1089/neu.2020.7508. Epub 2021 May 18.
Children frequently present to an Emergency Department (ED) after concussion, and headache is the most commonly associated symptom. Recent guidelines emphasize the importance of analgesia for post-concussion headache (PCH), yet evidence to inform treatment is lacking. We sought to characterize abortive therapies used to manage refractory PCH in the pediatric ED and factors associated with treatment. A scenario-based survey was distributed to ED physicians at all 15 Canadian tertiary pediatric centers. Participants were asked questions regarding ED treatment of acute (48 h) and persistent (1 month) PCH refractory to appropriate doses of acetaminophen/ibuprofen. Logistic regression was used to assess factors associated with treatment. Response rate was 63% (137/219). Nearly all physicians (128/137, 93%) endorsed treatment in the ED for acute PCH of severe intensity, with most selecting intravenous treatments (116/137, 84.7%). Treatments were similar for acute and persistent PCH. The most common treatments were metoclopramide (72%), physiologic saline (47%), and nonsteroidal anti-inflammatory agents (NSAIDS; 35%). Second-line ED treatments were more variable. For acute PCH of moderate intensity, overall treatment was lower (102/137, 74%; < 0.0001), and NSAIDS (48%) were most frequently selected. In multi-variable regression analyses, no physician- or ED-level factor was associated with receiving treatment, or treatment using metoclopramide specifically. Treatment for refractory PCH in the pediatric ED is highly variable. Importantly, patients with severe PCH are most likely to receive intravenous therapies, often with metoclopramide, despite a paucity of evidence supporting these choices. Further research is urgently needed to establish the comparative effectiveness of pharmacotherapeutic treatments for children with refractory PCH.
儿童脑震荡后常前往急诊科(ED)就诊,头痛是最常见的相关症状。近期指南强调了针对脑震荡后头痛(PCH)进行镇痛的重要性,但缺乏指导治疗的证据。我们旨在描述用于处理儿科急诊科难治性PCH的中止疗法以及与治疗相关的因素。我们向加拿大所有15家三级儿科中心的急诊科医生发放了基于情景的调查问卷。参与者被问及有关对适当剂量对乙酰氨基酚/布洛芬难治的急性(48小时)和持续性(1个月)PCH在急诊科治疗的问题。使用逻辑回归来评估与治疗相关的因素。回复率为63%(137/219)。几乎所有医生(128/137,93%)认可在急诊科对重度急性PCH进行治疗,大多数选择静脉治疗(116/137,84.7%)。急性和持续性PCH的治疗方法相似。最常用的治疗方法是甲氧氯普胺(72%)、生理盐水(47%)和非甾体抗炎药(NSAIDS;35%)。二线急诊科治疗方法差异更大。对于中度强度的急性PCH,总体治疗率较低(102/137,74%;<0.0001),最常选择的是NSAIDS(48%)。在多变量回归分析中,没有医生或急诊科层面的因素与接受治疗或具体使用甲氧氯普胺治疗相关。儿科急诊科对难治性PCH的治疗差异很大。重要的是,尽管缺乏支持这些选择的证据,但重度PCH患者最有可能接受静脉治疗,通常使用甲氧氯普胺。迫切需要进一步研究以确定难治性PCH儿童药物治疗的相对有效性。